An improved antiinflammatory composition and method of treating inflammation which employs a combination of an antiinflammatory agent (e.g. indomethacin or an oxicam) with a histamine-H.sub.2 antagonist selected from the group consisting of 2-guanidino-4-(4-imidazolyl)thiazole, 2-guanidino-4-(2-methyl-4-imidazolyl )thiazole, 2-(N-benzyl-N'-guanidino)-4-(2-methyl-4-imidazolyl)thiazole, 2-(N-pentyl-N'-guanidino)-4-(2-methyl-4-imidazolyl)thiazole and 2-guanidino-4-[2-(hexylamino)-4-imidazolyl]thiaz...

Azolylmethylcycloacetals of the formula I ##STR1## where R is phenyl which can be substituted by halogen, or is C.sub.1 -C.sub.6 -alkyl, R.sup.1 is hydrogen or C.sub.1 -C.sub.3 -alkyl, Z is CH or N, and m is 0 or 1, and their physiologically tolerated addition salts with acids and their preparation are described. The novel substances have an antimycotic action.

A medicament package comprising a rigid container having an end wall, side walls and an open end. A resilient closure which seals said open end of said rigid container, said resilient closure having an upper and lower portion, the lower portion being received in the open end of said rigid container and sealing same, the upper portion of said resilient closure projecting beyond the outer extremity of the open end of said container. A fluid pathway extending longitudinally through both portions of...

Benzimidazole-2-sulfonamide and imidazopyridine-2-sulfonamide derivatives corresponding to the general formula I: ##STR1## and their pharmaceutically acceptable salts, especially those of the formula in which: Z.sup.1 to Z.sup.4 represent a nitrogen atom or a substituted or unsubstituted carbon atom; R.sup.1 and R.sup.2 represent a hydrogen atom or an alkyl, alkylaryl, alkylcarbonylalkyl, alkylcarbonylaryl, alkylcarbonylheteroaryl, cycloalkyl, carboxyalkyl, acyl or nitro radical, or alternativel...

Phenylpiperidylamines of the formula I ##STR1## R.sup.1 is H, NO.sub.2, R.sup.4 SO.sub.2 NH, ##STR2## N.dbd.C, CF.sub.3, CF.sub.3 O, F, Cl, Br, C.sub.1 -C.sub.4 -alkyl, R.sup.3 O, CO.sub.2 R.sup.3, CHO, CH.dbd.NOR.sup.3, CH.sub.3 OR.sup.3 and R.sup.2 is H, F, Cl, Br, C.sub.1 -C.sub.4 -alkyl or R.sup.4 O, where R.sup.1 and R.sup.2 are not both H, R.sup.3 is H or R.sup.4, R.sup.4 is C.sub.1 -C.sub.4 -alkyl or phenyl, n is 1, 2, 3 or 4 and Ar is ##STR3## and the physiologically tolerated salts ther...

The method of combating bacterial infection of fish which comprises supplying to such fish or to their water an antibacterially effective amount of a quinoline derivative, salt or hydrate thereof of the formula ##STR1## in which R.sub.1 is hydrogen or a lower alkyl or lower hydroxy alkyl group, and R.sub.2 is hydrogen or a lower alkyl group.

Targeted drug conjugates which enable a large number of molecules of drug to be directed to a cell by a single molecule of antibody are provided. The invention also provides intermediates for the synthesis of such conjugates and cytotoxic drugs modified in accordance with the cluster concept of the invention.

A diagnostic drug and a diagnostic kit for autoimmune diseases including at least one of a polypeptide selected from an HMG-1 family, a polypeptide selected from an HMG-2 family, a fragment thereof which is reactable with an antibody of an autoimmune disease patient, and a method for detecting an antibody of an autoimmune disease patient using the same are provided.

Novel multibinding compounds are disclosed. The compounds of this invention comprise 2-10 ligands covalently connected, each of the ligands being capable of binding to a ligand binding site in a Ca.sup.++ channel , thereby modulating the biological activities thereof.

The invention involves methods and products related to the micronization of hydrophobic drugs. A method of micronizing hydrophobic drugs using a set of solutions including an aqueous solution is provided. The invention also relates to products of micronized hydrophobic drugs and related methods of use.